Exact Mass: 425.2175

Exact Mass Matches: 425.2175

Found 97 metabolites which its exact mass value is equals to given mass value 425.2175, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

M2 di-hydroxylated metabolite

2-(1-{1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl}-4-hydroxy-1H-indol-6-yl)-2-hydroxy-N-methylethanimidic acid

C24H28FN3O3 (425.2115)

M2 di-hydroxylated metabolite is a metabolite of saquinavir. Saquinavir is an antiretroviral drug used in HIV therapy. It falls in the protease inhibitor class. Two formulations have been marketed: a hard-gel capsule formulation of the mesylate, with trade name Invirase, which requires combination with ritonavir to increase the saquinavir bioavailability; a soft-gel capsule formulation of saquinavir, with trade name Fortovase. Both formulations are generally used as a component of highly active antiretroviral therapy (HAART). (Wikipedia)

(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

C21H27N7O3 (425.2175)

Revexepride

4-Amino-5-chloro-N-{[3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl]methyl}-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboximidate

C21H32ClN3O4 (425.2081)

Gly Gly His Arg

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

C16H27N9O5 (425.2135)

Gly Gly Arg His

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanoic acid

C16H27N9O5 (425.2135)

Gly His Gly Arg

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]acetamido}-5-carbamimidamidopentanoic acid

C16H27N9O5 (425.2135)

Gly His Arg Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]acetic acid

C16H27N9O5 (425.2135)

Gly Arg Gly His

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]acetamido}-3-(1H-imidazol-4-yl)propanoic acid

C16H27N9O5 (425.2135)

Gly Arg His Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]acetic acid

C16H27N9O5 (425.2135)

His Gly Gly Arg

(2S)-2-(2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}acetamido)-5-carbamimidamidopentanoic acid

C16H27N9O5 (425.2135)

His Gly Arg Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-5-carbamimidamidopentanamido]acetic acid

C16H27N9O5 (425.2135)

His Arg Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]acetamido}acetic acid

C16H27N9O5 (425.2135)

Asn His Arg

C16H27N9O5 (425.2135)

Asn Pro Pro Val

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-methylbutanoic acid

C19H31N5O6 (425.2274)

Asn Pro Val Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

C19H31N5O6 (425.2274)

Asn Val Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C19H31N5O6 (425.2274)

Pro Asn Pro Val

(2S)-2-{[(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanoic acid

C19H31N5O6 (425.2274)

Pro Asn Val Pro

(2S)-1-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

C19H31N5O6 (425.2274)

Pro Pro Asn Val

(2S)-2-[(2S)-3-carbamoyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}propanamido]-3-methylbutanoic acid

C19H31N5O6 (425.2274)

Pro Pro Val Asn

(2S)-3-carbamoyl-2-[(2S)-3-methyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}butanamido]propanoic acid

C19H31N5O6 (425.2274)

Pro Val Asn Pro

(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]propanoyl]pyrrolidine-2-carboxylic acid

C19H31N5O6 (425.2274)

Pro Val Pro Asn

(2S)-3-carbamoyl-2-{[(2S)-1-[(2S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]butanoyl]pyrrolidin-2-yl]formamido}propanoic acid

C19H31N5O6 (425.2274)

Arg Gly Gly His

(2S)-2-(2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}acetamido)-3-(1H-imidazol-4-yl)propanoic acid

C16H27N9O5 (425.2135)

Arg Gly His Gly

2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}-3-(1H-imidazol-4-yl)propanamido]acetic acid

C16H27N9O5 (425.2135)

Arg His Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]acetamido}acetic acid

C16H27N9O5 (425.2135)

His Asn Arg

C16H27N9O5 (425.2135)

Val Asn Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C19H31N5O6 (425.2274)

Val Pro Asn Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C19H31N5O6 (425.2274)

Val Pro Pro Asn

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C19H31N5O6 (425.2274)

Divaleroylphosphatidylcholine

3,5,9-Trioxa-4-phosphatetradecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxopentyl)oxy]-, inner salt, 4-oxide, (R)-

C18H36NO8P (425.2178)

PC(5:0/5:0)[U]

3,5,9-Trioxa-4-phosphatetradecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxopentyl)oxy]-, inner salt, 4-oxide

C18H36NO8P (425.2178)

PC 10:0

1,2-divaleryl-sn-glycero-3-phosphocholine

C18H36NO8P (425.2178)

2-(4,6-Diphenyl-1,3,5-triazin-2-yl)-5-[(hexyl)oxy]-phenol

C27H27N3O2 (425.2103)

(S)-BnCH2-PyBox, (S,S)-2,6-Bis(4-benzylmethyl-2-oxazolin-2-yl)pyridine

C27H27N3O2 (425.2103)

GSK690693

(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

C21H27N7O3 (425.2175)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C155764 - AKT Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3]. GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3].

(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

C21H27N7O3 (425.2175)

(2R,3R,3aS,9bS)-N-cyclohexyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C24H28FN3O3 (425.2115)

(2S,3S,3aR,9bR)-N-cyclohexyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C24H28FN3O3 (425.2115)

(4e)-3-({[(1s)-2-carboxy-1-[(2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl)-c-hydroxycarbonimidoyl]ethyl]-c-hydroxycarbonimidoyl}methyl)oct-4-enoic acid

C20H31N3O7 (425.2162)

(1s,14s,17r,22r)-10,11-dihydroxy-14,18,18,22-tetramethyl-13-oxa-8-azapentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁷,²²]docosa-3(12),4,6,8,10-pentaene-7-carboxylic acid

C25H31NO5 (425.2202)

methyl (1r,5s,6r,9r,10s,20r)-9-[(acetyloxy)methyl]-20-hydroxy-5-methyl-3-azahexacyclo[11.5.1.1⁶,¹⁰.0¹,⁹.0²,⁶.0¹⁶,¹⁹]icosa-2,13(19),16-triene-17-carboxylate

C25H31NO5 (425.2202)

7-(2-hydroxyethyl)-9a-methyl-3-octanoyl-6-(prop-1-en-1-yl)furo[3,2-g]isoquinoline-2,9-dione

C25H31NO5 (425.2202)

7-(2-hydroxyethyl)-9a-methyl-3-octanoyl-6-[(1z)-prop-1-en-1-yl]furo[3,2-g]isoquinoline-2,9-dione

C25H31NO5 (425.2202)